Risperdal Stroke Danger
Risperdal is a very lucrative schizophrenia drug for Johnson & Johnson, bringing in annual global sales of $2.1 billion. The second biggest selling medicine for J&J, Risperdal was only approved for schizophrenia, though Risperdal is often prescribed to control behavioral disorders in elderly patients. Antipsychotic medications can often control some schizophrenic symptoms, but in early April 2003 reports that there may be an increased risk of Risperdal stroke among elderly patients taking Risperdal.
Johnson & Johnson announced that in light of the Risperdal stroke connection the company would be sending out letters to thousands of U.S. physicians to inform them of the increased risk of Risperdal stroke that had been reported. In addition, the company announced the Risperdal package-insert label would be changed to include more specific information of the possibility of Risperdal stroke occurrences.
Public Citizen consumer group pharmacist and research analyst Larry Sasich believes that there are worrisome safety implications with Risperdal clinical trials. The Risperdal clinical trials involved Alzheimer patients that Sasich said developed Risperdal strokes in a much higher occurrence as compared to placebo recipients. There were 29 Risperdal stroke and stroke-related events amongst the 764 patients that were tested in four specific trials, amounting to 4% of all patients. There were four Risperdal deaths as well, compared to just one death in placebo recipients.
The implications that Risperdal stroke occurrences are more likely to occur should result in a higher accountability for prescribing Risperdal to non-schizophrenic patients, which Risperdal is not approved for. The controversial aspect of the Risperdal stroke announcement was the fact that J&J had already issued a Canadian Risperdal stroke letter in October 2002. The Canadian Risperdal stroke warnings cited 37 reports of Risperdal stroke or Risperdal stroke-like events, including 16 deaths.
Many patients are concerned that serious events, such as Risperdal strokes, are not promptly reported to physicians and patients because of fears that the safety warnings will hurt sales. The J&J spokesman at the time of the U.S. Risperdal stroke warning said that, an update to the Risperdal label is being made, and we will be sending out letters to health care professionals soon, however it still took an extra six months for the U.S. Risperdal stroke warning to be issued.
The result of a Risperdal stroke can affect the entire body of the Risperdal patient. Depending on the severity of the Risperdal stroke paralysis, cognitive effects, emotional problems, speech difficulties, loss of mobility, in addition to other adverse effects could be suffered. If you have taken Risperdal and have suffered a Risperdal stroke or any other Risperdal side effect, please contact us to confer with a Risperdal attorney.
For more information regarding the Risperdal Stroke danger, Contact our Risperdal Side Effect Attorneys for a FREE Evaluation! CLICK HERE!